{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T08:55:12Z","timestamp":1670489712332},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,3,16]],"date-time":"2012-03-16T00:00:00Z","timestamp":1331856000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s11899-012-0118-1","type":"journal-article","created":{"date-parts":[[2012,3,15]],"date-time":"2012-03-15T06:55:16Z","timestamp":1331794516000},"page":"109-115","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Trials in Chronic Myeloid Leukemia"],"prefix":"10.1007","volume":"7","author":[{"given":"Susanne","family":"Saussele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Pfirrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,3,16]]},"reference":[{"key":"118_CR1","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","volume":"109","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Berger U, Pfirrmann M, et al. Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia. Blood. 2007;109:4686\u201392.","journal-title":"Blood"},{"key":"118_CR2","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","volume":"29","author":"R Hehlmann","year":"2011","unstructured":"\u2022 Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800\u00a0mg\/d versus 400\u00a0mg\/d versus 400\u00a0mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011;29:1634\u201342. CML study IV of the German CML study group. Results demonstrated significant better MMR rates at 12\u00a0months (primary study endpoint) of tolerability adapted IM 800 vs. IM 400.","journal-title":"J Clin Oncol"},{"key":"118_CR3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"S O'Brien","year":"2003","unstructured":"O'Brien S, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004.","journal-title":"N Engl J Med"},{"key":"118_CR4","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"\u2022\u2022 Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041\u201351. ELN recommendations on managing CML.","journal-title":"J Clin Oncol"},{"key":"118_CR5","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","volume":"114","author":"M Deininger","year":"2009","unstructured":"Deininger M, O'Brien SG, Guilhot F, et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) treated with imatinib. Blood. 2009;114:1126.","journal-title":"Blood"},{"key":"118_CR6","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876\u201380.","journal-title":"Science"},{"key":"118_CR7","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1126\/science.293.5538.2163a","volume":"293","author":"A Hochhaus","year":"2001","unstructured":"Hochhaus A, Kreil S, Corbin A, et al. Roots of clinical resistance to STI-571 cancer therapy. Science. 2001;293:2163.","journal-title":"Science"},{"key":"118_CR8","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.hoc.2011.09.005","volume":"25","author":"T Ernst","year":"2011","unstructured":"Ernst T, La Ros\u00e9e P, M\u00fcller MC, Hochhaus A. BCR-ABL mutations in chronic myeloid leukemia. Hematol Oncol Clin North Am. 2011;25:997\u20131008.","journal-title":"Hematol Oncol Clin North Am"},{"key":"118_CR9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/shem.2003.50045","volume":"40","author":"A Hochhaus","year":"2003","unstructured":"Hochhaus A. Cytogenetic and molecular mechanisms of resistance to imatinib. Semin Hematol. 2003;40:69\u201379.","journal-title":"Semin Hematol"},{"key":"118_CR10","first-page":"461","volume":"2009","author":"D Bixby","year":"2009","unstructured":"Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. ASH Educ Program Book. 2009;2009:461\u201376.","journal-title":"ASH Educ Program Book"},{"key":"118_CR11","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1200\/JCO.2008.20.3869","volume":"27","author":"JE Cortes","year":"2009","unstructured":"Cortes JE, Kantarjian HM, Goldberg SL, et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol. 2009;27:4754\u20139.","journal-title":"J Clin Oncol"},{"key":"118_CR12","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","volume":"363","author":"C Preudhomme","year":"2010","unstructured":"\u2022 Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363:2511\u201321. French Spirit trial. Results demonstrated significant shorter time to \u201coptimal molecular response\u201d of IM+IFN vs. IM 400.","journal-title":"N Engl J Med"},{"key":"118_CR13","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"\u2022\u2022 Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139. Nilotonib showed significantly higher rate of MMR at 12 months when compared to imatinib.","journal-title":"N Engl J Med"},{"key":"118_CR14","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"\u2022\u2022 Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260\u201370. Dasatinib showed significantly higher rate of confirmed CCR at 12 months when compared to imatinib.","journal-title":"N Engl J Med"},{"key":"118_CR15","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/leu.2011.116","volume":"25","author":"M Pfirrmann","year":"2011","unstructured":"\u2022 Pfirrmann M, Hochhaus A, Lauseker M, et al. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia. 2011;25:1433\u20138. Statistical considerations on the analysis of CML studies including explanation of the impact of the cumulative incidence function.","journal-title":"Leukemia"},{"key":"118_CR16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/blood-2011-05-355594","volume":"118","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Maru A, Souza CAAD, et al. Bosutinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia\u2013BELA trial: 24-month follow-up. Blood. 2011;118:455.","journal-title":"Blood"},{"key":"118_CR17","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1200\/JCO.2010.33.9176","volume":"29","author":"H Kantarjian","year":"2011","unstructured":"Kantarjian H, Cortes J. Considerations in the management of patients with Philadelphia chromosome\u2013positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. J Clin Oncol. 2011;29:1512\u20136.","journal-title":"J Clin Oncol"},{"key":"118_CR18","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","volume":"26","author":"H Putter","year":"2007","unstructured":"Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26:2389\u2013430.","journal-title":"Stat Med"},{"key":"118_CR19","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809\u201320.","journal-title":"Blood"},{"key":"118_CR20","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.2010.33.4169","volume":"29","author":"H Kantarjian","year":"2011","unstructured":"Kantarjian H, O'Brien S, Jabbour E, et al. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol. 2011;29:3173\u20138.","journal-title":"J Clin Oncol"},{"key":"118_CR21","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"118_CR22","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood. 1984;63:789\u201399.","journal-title":"Blood"},{"key":"118_CR23","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon Alfa. Writing committee for the collaborative CML prognostic factors project group. J Natl Canc Inst. 1998;90:850\u20138.","journal-title":"J Natl Canc Inst"},{"key":"118_CR24","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118:686\u201392.","journal-title":"Blood"},{"key":"118_CR25","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","volume":"101","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003;101:473\u20135.","journal-title":"Blood"},{"key":"118_CR26","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","volume":"113","author":"E Jabbour","year":"2009","unstructured":"Jabbour E, Kantarjian HM, Jones D, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood. 2009;113:2154\u201360.","journal-title":"Blood"},{"key":"118_CR27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2003-01-0025","volume":"102","author":"J Cortes","year":"2003","unstructured":"Cortes J, Giles F, O'Brien S, et al. Results of high-dose imatinib mesylate in patients with Philadelphia chromosome positive chronic myeloid leukemia after failure of interferon-alfa. Blood. 2003;102:83\u20136.","journal-title":"Blood"},{"key":"118_CR28","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","volume":"103","author":"H Kantarjian","year":"2004","unstructured":"Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873\u20138.","journal-title":"Blood"},{"key":"118_CR29","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood-2007-08-103499","volume":"113","author":"F Castagnetti","year":"2009","unstructured":"Castagnetti F, Palandri F, Amabile M, et al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood. 2009;113:3428\u201334.","journal-title":"Blood"},{"key":"118_CR30","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","volume":"112","author":"TP Hughes","year":"2008","unstructured":"Hughes TP, Branford S, White DL, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600\u00a0mg\/day of imatinib as initial therapy. Blood. 2008;112:3965\u201373.","journal-title":"Blood"},{"key":"118_CR31","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","volume":"113","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Rosti G, Castagnetti F, et al. Comparison of imatinib 400\u00a0mg and 800\u00a0mg daily in the front-line treatment of high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study. Blood. 2009;113:4497\u2013504.","journal-title":"Blood"},{"key":"118_CR32","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400\u00a0mg versus 800\u00a0mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010;28:424\u201330.","journal-title":"J Clin Oncol"},{"key":"118_CR33","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","volume":"458","author":"MA Essers","year":"2009","unstructured":"Essers MA, Offner S, Blanco-Bose WE, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458:904\u20138.","journal-title":"Nature"},{"key":"118_CR34","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","volume":"28","author":"A Burchert","year":"2010","unstructured":"Burchert A, Mueller MC, Kostrewa P, et al. Sustained molecular response with interferon Alfa maintenance after induction therapy with imatinib plus interferon Alfa in patients with chronic myeloid leukemia. J Clin Oncol. 2010;28:1429\u201335.","journal-title":"J Clin Oncol"},{"key":"118_CR35","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1055\/s-0038-1634010","volume":"44","author":"M Pfirrmann","year":"2005","unstructured":"Pfirrmann M, Hasford J. A simulation study using validated prognostic factors to assess expected long-term survival. Methods Inform Med. 2005;44:577\u201383.","journal-title":"Methods Inform Med"},{"key":"118_CR36","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","volume":"118","author":"B Simonsson","year":"2011","unstructured":"\u2022 Simonsson B, Gedde-Dahl T, Markevarn B, et al. Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood. 2011;118:3228\u201335. Nordic study group trial showing superiority of IM + IFN.","journal-title":"Blood"},{"key":"118_CR37","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2011-01-330217","volume":"118","author":"H Johnson-Ansah","year":"2011","unstructured":"Johnson-Ansah H, Guilhot J, Rousselot P, et al. Pegylated interferon a2a (PegIFN) at the dose of 45{mu}g per week in combination with imatinib 400\u00a0mg is the recommended initial dose for patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP): results from the French SPIRIT trial of the French CML Group (FI LMC). Blood. 2011;118:456.","journal-title":"Blood"},{"key":"118_CR38","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ajh.22076","volume":"86","author":"A Gafter-Gvili","year":"2011","unstructured":"Gafter-Gvili A, Leader A, Gurion R, et al. High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients\u2014systematic review and meta-analysis. Am J Hematol. 2011;86:657\u201362.","journal-title":"Am J Hematol"},{"key":"118_CR39","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"\u2022 Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12:841\u201351. Most recent update with 24-months follow-up data of the ENESTnd trial.","journal-title":"Lancet Oncol"},{"key":"118_CR40","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"\u2022 Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119:1123\u20139. Most recent update with 24-months follow-up data of the DASISION trial.","journal-title":"Blood"},{"key":"118_CR41","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1185\/03007995.2011.576238","volume":"27","author":"JE Signorovitch","year":"2011","unstructured":"Signorovitch JE, Wu EQ, Betts KA, et al. Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. Curr Med Res Opin. 2011;27:1263\u201371.","journal-title":"Curr Med Res Opin"},{"key":"118_CR42","first-page":"3434","volume":"116","author":"C Gambacorti-Passerini","year":"2010","unstructured":"Gambacorti-Passerini C, Khoury HJ, Pinczowski H, et al. Clinical activity of bosutinib by mutational status in patients with previously treated Philadelphia chromosome-positive leukemias. ASH Annu Meet Abstr. 2010;116:3434.","journal-title":"ASH Annu Meet Abstr"},{"key":"118_CR43","first-page":"109","volume":"118","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. Initial findings from the PACE trial: a pivotal phase 2 study of ponatinib in patients with CML and Ph + ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. ASH Annu Meet Abstr. 2011;118:109.","journal-title":"ASH Annu Meet Abstr"},{"key":"118_CR44","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.20.1.214","volume":"20","author":"FX Mahon","year":"2002","unstructured":"Mahon FX, Delbrel X, Cony-Makhoul P, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol. 2002;20:214\u201320.","journal-title":"J Clin Oncol"},{"key":"118_CR45","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","volume":"98","author":"F Bonifazi","year":"2001","unstructured":"Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001;98:3074\u201381.","journal-title":"Blood"},{"key":"118_CR46","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2\u00a0years. Blood. 2007;109:58\u201360.","journal-title":"Blood"},{"key":"118_CR47","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"\u2022 Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2\u00a0years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029\u201335. The trial provides results on molecular remission durability after treatment discontinuation.","journal-title":"Lancet Oncol"},{"key":"118_CR48","first-page":"423","volume":"96","author":"D Rea","year":"2011","unstructured":"Rea D, Rousselot P, Nicolini F, et al. Cessation of dasatinib or nilotinib therapy in chronic-phase chronic myeloid leukemia patients with sustained complete molecular responses. Haematologica. 2011;96:423\u20134.","journal-title":"Haematologica"},{"key":"118_CR49","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1200\/JCO.2011.34.6056","volume":"29","author":"EL Korn","year":"2011","unstructured":"Korn EL, Freidlin B, Abrams JS. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol. 2011;29:2439\u201342.","journal-title":"J Clin Oncol"},{"key":"118_CR50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28\u201337.","journal-title":"Blood"},{"key":"118_CR51","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","volume":"23","author":"MC M\u00fcller","year":"2009","unstructured":"M\u00fcller MC, Cross NC, Erben P, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia. 2009;23:1957\u201363.","journal-title":"Leukemia"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-012-0118-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-012-0118-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-012-0118-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T06:36:55Z","timestamp":1593844615000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-012-0118-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,16]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["118"],"URL":"https:\/\/doi.org\/10.1007\/s11899-012-0118-1","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,16]]}}}